For patients already diagnosed with PD, GBA1 testing may provide further information surrounding disease course and treatment options, enable early enrolment into clinical trials investigating gene‐modifying therapies, and inform on family members' risk of harboring GBA1 variants. This evidence concerns the gene GBA1 and Parkinson disease.